ROR1 and mantle cell lymphoma: This heterogeneity suggests that any potential trial patient selection strategy for MCL, DLBCL and FL should include ROR1 positive cases and exclude ROR1 negative ones to assure successful development of new therapeutic modalities targeting ROR1.